Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy.
Santer FR, Erb HH, Oh SJ, Handle F, Feiersinger GE, Luef B, Bu H, Schäfer G, Ploner C, Egger M, Rane JK, Maitland NJ, Klocker H, Eder IE, Culig Z.
Santer FR, et al.
Oncotarget. 2015 Mar 20;6(8):6105-22. doi: 10.18632/oncotarget.3368.
Oncotarget. 2015.
PMID: 25749045
Free PMC article.